ScholarIQanswers from OpenAlex & ORCID
Massimo Federico
ResearcherPublications, citations & collaboration network
Massimo Federico is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Massimo Federico have?
ScholarIQindexed works
Massimo Federico has 552 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Massimo Federico have?
ScholarIQcitation count
Massimo Federico has 27,353 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Massimo Federico?
ScholarIQh-index
Massimo Federico has an h-index of 74 in OpenAlex.
What is the i10-index of Massimo Federico?
ScholarIQi10-index
Massimo Federico has an i10-index of 257 in OpenAlex.
What is the ORCID of Massimo Federico?
ScholarIQorcid
The ORCID for Massimo Federico is on the source record.
What is the OpenAlex record for Massimo Federico?
ScholarIQopenalex
The OpenAlex for Massimo Federico is on the source record.
What are the most-cited papers on Massimo Federico?
ScholarIQmost cited works
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Peter Johnson, Massimo Federico, Amy A. Kirkwood, Alexander Fosså, Leanne Berkahn, Angelo Michele Carella, Francesco d’Amore, Gunilla Enblad, Antonella Franceschetto, Michael Fulham, Stefano Luminari, Michael O'Doherty, Pip Patrick, Thomas A. Roberts, Gamal Sidra, Lindsey Stevens, Paul Smith, Judith Trotman, Zaid Viney, John Radford, Sally F. Barrington
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico, Monica Bellei, Luigi Marcheselli, Stefano Luminari, Armando López‐Guillermo, Umberto Vitolo, Barbara Pro, Stefano Pileri, Alessandro Pulsoni, Pierre Soubeyran, Sergio Cortelazzo, Giovanni Martinelli, Maurizio Martelli, Luigi Rigacci, Luca Arcaini, Francesco Di Raimondo, Francesco Merli, Elena Sabattini, Peter McLaughlin, Philippe Solal‐Céligny
Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study)
Francesco Sardanelli, Franca Podo, Filippo Santoro, Siranoush Manoukian, S Bergonzi, Giovanna Trecate, Daniele Vergnaghi, Massimo Federico, Laura Cortesi, Stefano Corcione, Sandro Morassut, C. Di Maggio, A Cilotti, Laura Martincich, Massimo Calabrese, Chiara Zuiani, Lorenzo Preda, Bernardo Bonanni, Luca Alessandro Carbonaro, Alma Contegiacomo, Pietro Panizza, Ernesto Di Cesare, Antonella Savarese, M Crecco, Daniela Turchetti, M. Tonutti, Paolo Belli, Alessandro Del Maschio
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico, Stefano Luminari, Emilio Iannitto, Giuseppe Polimeno, Luigi Marcheselli, Antonella Montanini, Antonio La Sala, Francesco Merli, Caterina Stelitano, Samantha Pozzi, Renato Scalone, Nicola Di Renzo, Pellegrino Musto, Luca Baldini, Giulia Cervetti, F. Angrilli, Patrizio Mazza, Maura Brugiatelli, Paolo G. Gobbi
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi
Massimo Federico, Stefano Luminari, Alessandra Dondi, Alessandra Tucci, Umberto Vitolo, Luigi Rigacci, Francesco Di Raimondo, Angelo Michele Carella, Alessandro Pulsoni, Francesco Merli, Luca Arcaini, F. Angrilli, Caterina Stelitano, Gianluca Gaïdano, Matteo Dell’Olio, Luigi Marcheselli, Vito Franco, Sara Galimberti, Stefano Sacchi, Maura Brugiatelli